Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call
Zevra Therapeutics (NasdaqGS: ZVRA), a commercial-stage rare disease therapy company, has scheduled its second quarter 2025 financial results announcement for Tuesday, August 12, 2025. The company will release its corporate and financial results after market close, followed by a conference call and audio webcast at 4:30 p.m. ET.
Investors can access the webcast through Zevra's website investor relations section. The conference call can be joined via telephone using U.S. dial-in (800) 245-3047 or International +1 (203) 518-9765 with Conference ID: ZVRAQ225. A replay will be available on the company's website for 90 days following the presentation.
Zevra Therapeutics (NasdaqGS: ZVRA), un'azienda in fase commerciale specializzata in terapie per malattie rare, ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per martedì 12 agosto 2025. La società pubblicherà i risultati aziendali e finanziari dopo la chiusura del mercato, seguiti da una teleconferenza e una trasmissione audio in webcast alle 16:30 ET.
Gli investitori potranno accedere al webcast tramite la sezione relazioni con gli investitori del sito web di Zevra. La teleconferenza sarà raggiungibile telefonicamente con il numero statunitense (800) 245-3047 o internazionale +1 (203) 518-9765, utilizzando l'ID conferenza: ZVRAQ225. Una registrazione sarà disponibile sul sito web della società per 90 giorni dopo la presentazione.
Zevra Therapeutics (NasdaqGS: ZVRA), una empresa en etapa comercial dedicada a terapias para enfermedades raras, ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el martes 12 de agosto de 2025. La compañía publicará sus resultados corporativos y financieros después del cierre del mercado, seguido de una llamada conferencia y una transmisión en audio webcast a las 4:30 p.m. ET.
Los inversores podrán acceder al webcast a través de la sección de relaciones con inversores en el sitio web de Zevra. La llamada conferencia se podrá unir por teléfono usando el número de EE. UU. (800) 245-3047 o internacional +1 (203) 518-9765 con el ID de conferencia: ZVRAQ225. Una repetición estará disponible en el sitio web de la compañía durante 90 días después de la presentación.
Zevra Therapeutics (NasdaqGS: ZVRA)는 상업 단계의 희귀 질환 치료 회사로, 2025년 2분기 재무 결과 발표를 2025년 8월 12일 화요일로 예정했습니다. 회사는 시장 마감 후 기업 및 재무 결과를 발표하며, 이어서 동부 표준시 오후 4시 30분에 컨퍼런스 콜과 오디오 웹캐스트가 진행됩니다.
투자자들은 Zevra 웹사이트의 투자자 관계 섹션을 통해 웹캐스트에 접속할 수 있습니다. 컨퍼런스 콜은 미국 내 전화번호 (800) 245-3047 또는 국제 전화번호 +1 (203) 518-9765를 통해 회의 ID: ZVRAQ225를 입력하여 참여할 수 있습니다. 발표 후 90일 동안 회사 웹사이트에서 다시보기가 제공됩니다.
Zevra Therapeutics (NasdaqGS: ZVRA), une entreprise en phase commerciale spécialisée dans les thérapies pour maladies rares, a prévu l'annonce de ses résultats financiers du deuxième trimestre 2025 pour mardi 12 août 2025. La société publiera ses résultats corporatifs et financiers après la clôture du marché, suivis d'une conférence téléphonique et d'une diffusion audio en webcast à 16h30 ET.
Les investisseurs pourront accéder au webcast via la section relations investisseurs du site web de Zevra. La conférence téléphonique pourra être rejointe par téléphone en composant le numéro américain (800) 245-3047 ou international +1 (203) 518-9765 avec l'ID de conférence : ZVRAQ225. Une rediffusion sera disponible sur le site de la société pendant 90 jours après la présentation.
Zevra Therapeutics (NasdaqGS: ZVRA), ein Unternehmen in der kommerziellen Phase, das Therapien für seltene Krankheiten anbietet, hat die Bekanntgabe der Finanzergebnisse für das zweite Quartal 2025 für Dienstag, den 12. August 2025 geplant. Das Unternehmen wird seine Unternehmens- und Finanzergebnisse nach Börsenschluss veröffentlichen, gefolgt von einer Telefonkonferenz und einem Audio-Webcast um 16:30 Uhr ET.
Investoren können über den Bereich Investor Relations auf der Website von Zevra auf den Webcast zugreifen. Die Telefonkonferenz kann über die US-Einwahlnummer (800) 245-3047 oder international +1 (203) 518-9765 mit der Konferenz-ID: ZVRAQ225 telefonisch verfolgt werden. Eine Aufzeichnung wird auf der Unternehmenswebsite für 90 Tage nach der Präsentation verfügbar sein.
- None.
- None.
Company will host conference call at 4:30 p.m. ET, on Tuesday, August 12, 2025
CELEBRATION, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it will report corporate and financial results for the second quarter 2025 on Tuesday, August 12, 2025, via a news release after the market close, and will host a conference call/audio webcast at 4:30 p.m. ET that day.
A link to the audio webcast will be accessible on the “Events & Presentations” page in the Investor Relations section of Zevra’s website at https://investors.zevra.com/.
To join via telephone, please use the following dial-in information:
- (800) 245-3047 (United States)
- +1 (203) 518-9765 (International)
- Conference ID: ZVRAQ225
A replay of the webcast will be available for 90 days beginning at approximately 5:30 p.m. ET. The replay will be accessible on the “Events & Presentations” page of Zevra’s website at https://investors.zevra.com/.
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. is a commercial-stage company combining science, data, and patient needs to create transformational therapies for rare diseases with limited or no treatment options. Our mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, the Company is overcoming complex drug development challenges to make new therapies available to the rare disease community.
For more information, please visit www.zevra.com or follow us on X and LinkedIn.
Caution Concerning Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding upcoming events or Zevra’s participation at such events. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Zevra’s Annual Report on Form 10-K for the year ended December 31, 2024, filed on March 12, 2025, and Zevra’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed on May 13, 2025, and Zevra’s other filings with the SEC. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.
Zevra Contact
Nichol Ochsner
+1 (732) 754-2545
nochsner@zevra.com
FAQ
When will Zevra Therapeutics (ZVRA) report Q2 2025 earnings?
How can investors access Zevra's Q2 2025 earnings call?
Where can I find the replay of Zevra's Q2 2025 earnings webcast?
What does Zevra Therapeutics (ZVRA) do?
